Autism Spectrum Disorder Therapeutics Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	162 Pages	Fortune Business Insights Pvt. Ltd.	October, 2024	FOB19224334

Best Price Guarantee
Price	from $4,850
Length	162 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	October, 2024
SKU	FOB19224334

Autism Spectrum Disorder Therapeutics Market

Growth Factors of Autism Spectrum Disorder Therapeutics Market

The autism spectrum disorder therapeutics market size was valued at USD 1.93 billion in 2023, and the market is now projected to grow from USD 2.01 billion in 2024 to USD 3.42 billion by 2032, exhibiting a CAGR of 7.9% during the forecast period of 2024-2032.

The lockdown caused by COVID-19 at first affected the healthcare companies and closed therapy centers, paused production and postponed therapy sessions for autistic children. However, ensuring a high level of stress in patients diagnosed with autism, as well as patients’ susceptibility to a viral infection, contributed to caregivers’ adoptive telehealth systems. This shift elevated generalized therapeutics and especially off label prescriptions such as antipsychotics, SSRIs, and sleep medications. Also, the increase in online platforms that traders used to purchase autism medications also benefited market growth during the pandemic.

The global market is being spurred forward by the continually increasing incidence of autism spectrum disorder (ASD), expanding the need for clinical research to find more efficacious treatments. This research needs to be done to help increase quality of life and refine treatments of patients with ASD. Since it strengthens the call for more specific approaches towards a growing population, it improves innovation and investment in therapeutic solutions that will help the people in need and their kin.

ASD is a lifelong developmental disorder which affects not only children and adults, but also their families and others who surround them. Autism is different in every individual, and most of them suffer from one or another complication – gastrointestinal problems, for example. It was in the 1980s and 1990s that theories which stated that the autistic persons may have a problem with the digestion of such proteins as the casein in milk or the gluten in wheat, began to be developed into various therapies. Even though many of these therapies have been ringed out their longevity, enzyme replacement therapy has received much attention as a crucial megatrend in the treatment of ASD, therefore, holds the opportunity to enhance the quality of lives of affected people.

Comprehensive Analysis of Autism Spectrum Disorder Therapeutics Market

The autism spectrum disorder therapeutics market growth is rising at an exponential rate due to its market segmentation. This market expansion rightly provides a thorough market breakdown near to the industry considering the leading supply and demand forces. These segmentations are methodically segregated by drug therapy analysis, by disease analysis, by age group analysis, and by distribution channel analysis. By drug therapy analysis include antipsychotic drugs, SSRIs/antidepressants, stimulants, sleep medications, and others. By disease analysis include autistic disorder, Asperger syndrome, pervasive developmental disorder, and others. By age group analysis include children and adults based on the age group. By distribution channel analysis include hospital pharmacies, drugs stores & retail pharmacies, and online pharmacies.

The North America region lead the autism spectrum disorder therapeutics market share by benefitting a market size of USD 1.12 billion in 2023 due to increasing prevalence of autism disorder.

The top players in the markets have a central responsibility in the healthcare industry to be sure of industrial prospectus development and to establish the market norms. These players include, Curemark, LLC, Alembic Pharmaceuticals Limited, Yamo Pharmaceuticals, PaxMedica, F. Hoffmann-La Roche Ltd, Aurobindo Pharma Ltd., Otsuka Holdings Co. Ltd., Janssen Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S these market players provide a level-playing competitive landscape.

In December 2021, F. Hoffmann-La Roche Ltd's drug pipeline candidate RO7017773 was in a phase 2 trial to evaluate its efficacy, safety, and tolerability in participants aged 15-45 with autism spectrum disorder (ASD), with plans for a regulatory filing in 2024.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2030

Base Year 2022

Estimated Year 2023

Forecast Period 2023-2030

Historical Period 2019-2021

Growth Rate CAGR of 7.9% from 2023 to 2030

Unit Value (USD billion)

Segmentation By Drug Therapy, Disease, Age Group, Distribution Channel, and Geography

By Drug Therapy

Antipsychotic Drugs

SSRIs/Antidepressants
Stimulants
Sleep Medications
Others

By Disease

Autistic Disorder

Asperger Syndrome
Pervasive Developmental Disorder (PDD)
Others

By Age Group

Children

Adults

By Distribution Channel

Hospital Pharmacies

Drug Stores & Retail Pharmacies
Online Pharmacies

By Geography

North America (By Drug Therapy, By Disease, By Age Group, By Distribution Channel, and By Country)

U.S. (By Disease)
Canada (By Disease)
Europe (By Drug Therapy, By Disease, By Age Group, By Distribution Channel, and By Country/Sub-Regions)
U.K. (By Disease)
Germany (By Disease)
France (By Disease)
Italy (By Disease)
Spain (By Disease)
Scandinavia (By Disease)
Rest of Europe (By Disease)
Asia Pacific (By Drug Therapy, By Disease, By Age Group, By Distribution Channel, and By Country/Sub-Regions)
China (By Disease)
Japan (By Disease)
India (By Disease)
Australia (By Disease)
Southeast Asia (By Disease)
Rest of Asia Pacific (By Disease)
Latin America (By Drug Therapy, By Disease, By Age Group, By Distribution Channel, and By Country/Sub-Regions)
Brazil (By Disease)
Mexico (By Disease)
Rest of Latin America (By Disease)
The Middle East & Africa (By Drug Therapy, By Disease, By Age Group, By Distribution Channel, and By Country/Sub-Regions)
GCC Countries (By Disease)
South Africa (By Disease)
Rest of the Middle East & Africa (By Disease)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology; 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities; 3.4. Market Trends
4. Key Insights: 4.1. Prevalence of Autism Spectrum Disorder– Key Countries/ Regions; 4.2. Key Industry Developments (Mergers, Acquisition and Partnerships); 4.3. Pipeline Analysis; 4.4. Economic Cost Burden for the Treatment of Autism Spectrum Disorder; 4.5. Regulatory and Reimbursement Scenario– Key Countries/ Regions; 4.6. Research and Development Analysis; 4.7. Impact of Covid-19 on the Market
5. Global Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2019-2030: 5.1. Market Analysis, Insights and Forecast – By Drug Therapy; 5.1.1. Antipsychotic Drugs; 5.1.2. SSRIs/Antidepressants; 5.1.3. Stimulants; 5.1.4. Sleep Medications; 5.1.5. Others; 5.2. Market Analysis, Insights and Forecast – By Disease; 5.2.1. Autistic Disorder; 5.2.2. Asperger Syndrome; 5.2.3. Pervasive Development Disorder (PDD); 5.2.4. Others; 5.3. Market Analysis, Insights and Forecast – By Age Group; 5.3.1. Children; 5.3.2. Adults; 5.4. Market Analysis, Insights and Forecast – By Distribution Channel; 5.4.1. Hospital Pharmacies; 5.4.2. Drug Stores & Retail Pharmacies; 5.4.3. Online Pharmacies; 5.5. Market Analysis, Insights and Forecast – By Region; 5.5.1. North America; 5.5.2. Europe; 5.5.3. Asia Pacific; 5.5.4. Latin America; 5.5.5. Middle East and Africa
6. North America Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2019-2030: 6.1. Market Analysis, Insights and Forecast – By Drug Therapy; 6.1.1. Antipsychotic Drugs; 6.1.2. SSRIs/Antidepressants; 6.1.3. Stimulants; 6.1.4. Sleep Medications; 6.1.5. Others; 6.2. Market Analysis, Insights and Forecast – By Disease; 6.2.1. Autistic Disorder; 6.2.2. Asperger Syndrome; 6.2.3. Pervasive Development Disorder (PDD); 6.2.4. Others; 6.3. Market Analysis, Insights and Forecast – By Age Group; 6.3.1. Children; 6.3.2. Adults; 6.4. Market Analysis, Insights and Forecast – By Distribution Channel; 6.4.1. Hospital Pharmacies; 6.4.2. Drug Stores & Retail Pharmacies; 6.4.3. Online Pharmacies; 6.5. Market Analysis, Insights and Forecast – By Country; 6.5.1. U.S.; 6.5.1.1. By Disease; 6.5.2. Canada; 6.5.2.1. By Disease
7. Europe Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2019-2030: 7.1. Market Analysis, Insights and Forecast – By Drug Therapy; 7.1.1. Antipsychotic Drugs; 7.1.2. SSRIs/Antidepressants; 7.1.3. Stimulants; 7.1.4. Sleep Medications; 7.1.5. Others; 7.2. Market Analysis, Insights and Forecast – By Disease; 7.2.1. Autistic Disorder; 7.2.2. Asperger Syndrome; 7.2.3. Pervasive Development Disorder (PDD); 7.2.4. Others; 7.3. Market Analysis, Insights and Forecast – By Age Group; 7.3.1. Children; 7.3.2. Adults; 7.4. Market Analysis, Insights and Forecast – By Distribution Channel; 7.4.1. Hospital Pharmacies; 7.4.2. Drug Stores & Retail Pharmacies; 7.4.3. Online Pharmacies; 7.5. Market Analysis, Insights and Forecast – By County/ Sub-region; 7.5.1. U.K; 7.5.1.1. By Disease; 7.5.2. Germany; 7.5.2.1. By Disease; 7.5.3. France; 7.5.3.1. By Disease; 7.5.4. Italy; 7.5.4.1. By Disease; 7.5.5. Spain; 7.5.5.1. By Disease; 7.5.6. Scandinavia; 7.5.6.1. By Disease; 7.5.7. Rest of Europe; 7.5.7.1. By Disease
8. Asia Pacific Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2019-2030: 8.1. Market Analysis, Insights and Forecast – By Drug Therapy; 8.1.1. Antipsychotic Drugs; 8.1.2. SSRIs/Antidepressants; 8.1.3. Stimulants; 8.1.4. Sleep Medications; 8.1.5. Others; 8.2. Market Analysis, Insights and Forecast – By Disease; 8.2.1. Autistic Disorder; 8.2.2. Asperger Syndrome; 8.2.3. Pervasive Development Disorder (PDD); 8.2.4. Others; 8.3. Market Analysis, Insights and Forecast – By Age Group; 8.3.1. Children; 8.3.2. Adults; 8.4. Market Analysis, Insights and Forecast – By Distribution Channel; 8.4.1. Hospital Pharmacies; 8.4.2. Drug Stores & Retail Pharmacies; 8.4.3. Online Pharmacies; 8.5. Market Analysis, Insights and Forecast – By Country/ Sub-region; 8.5.1. China; 8.5.1.1. By Disease; 8.5.2. Japan; 8.5.2.1. By Disease; 8.5.3. India; 8.5.3.1. By Disease; 8.5.4. Australia; 8.5.4.1. By Disease; 8.5.5. Southeast Asia; 8.5.5.1. By Disease; 8.5.6. Rest of Asia Pacific; 8.5.6.1. By Disease
9. Latin America Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2019-2030: 9.1. Market Analysis, Insights and Forecast – By Drug Therapy; 9.1.1. Antipsychotic Drugs; 9.1.2. SSRIs/Antidepressants; 9.1.3. Stimulants; 9.1.4. Sleep Medications; 9.1.5. Others; 9.2. Market Analysis, Insights and Forecast – By Disease; 9.2.1. Autistic Disorder; 9.2.2. Asperger Syndrome; 9.2.3. Pervasive Development Disorder (PDD); 9.2.4. Others; 9.3. Market Analysis, Insights and Forecast – By Age Group; 9.3.1. Children; 9.3.2. Adults; 9.4. Market Analysis, Insights and Forecast – By Distribution Channel; 9.4.1. Hospital Pharmacies; 9.4.2. Drug Stores & Retail Pharmacies; 9.4.3. Online Pharmacies; 9.5. Market Analysis, Insights and Forecast – By Country/ Sub-region; 9.5.1. Brazil; 9.5.1.1. By Disease; 9.5.2. Mexico; 9.5.2.1. By Disease; 9.5.3. Rest of Latin America; 9.5.3.1. By Disease
10. Middle East and Africa Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2019-2030: 10.1. Market Analysis, Insights and Forecast – By Drug Therapy; 10.1.1. Antipsychotic Drugs; 10.1.2. SSRIs/Antidepressants; 10.1.3. Stimulants; 10.1.4. Sleep Medications; 10.1.5. Others; 10.2. Market Analysis, Insights and Forecast – By Disease; 10.2.1. Autistic Disorder; 10.2.2. Asperger Syndrome; 10.2.3. Pervasive Development Disorder (PDD); 10.2.4. Others; 10.3. Market Analysis, Insights and Forecast – By Age Group; 10.3.1. Children; 10.3.2. Adults; 10.4. Market Analysis, Insights and Forecast – By Distribution Channel; 10.4.1. Hospital Pharmacies; 10.4.2. Drug Stores & Retail Pharmacies; 10.4.3. Online Pharmacies; 10.5. Market Analysis, Insights and Forecast – By Country/ Sub-region; 10.5.1. GCC; 10.5.1.1. By Disease; 10.5.2. South Africa; 10.5.2.1. By Disease; 10.5.3. Rest of Middle East and Africa; 10.5.3.1. By Disease
11. Competitive Analysis: 11.1. Global Market Share Analysis (2022); 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability)); 11.2.1. Curemark, LLC; 11.2.1.1. Overview,; 11.2.1.2. Products,; 11.2.1.3. SWOT Analysis,; 11.2.1.4. Recent Developments,; 11.2.1.5. Strategies,; 11.2.1.6. financials (Based on Availability); 11.2.2. Alembic Pharmaceuticals Limited.; 11.2.2.1. Overview,; 11.2.2.2. Products,; 11.2.2.3. SWOT Analysis,; 11.2.2.4. Recent Developments,; 11.2.2.5. Strategies,; 11.2.2.6. financials (Based on Availability); 11.2.3. Yamo Pharmaceuticals; 11.2.3.1. Overview,; 11.2.3.2. Products,; 11.2.3.3. SWOT Analysis,; 11.2.3.4. Recent Developments,; 11.2.3.5. Strategies,; 11.2.3.6. financials (Based on Availability); 11.2.4. PaxMedica; 11.2.4.1. Overview,; 11.2.4.2. Products,; 11.2.4.3. SWOT Analysis,; 11.2.4.4. Recent Developments,; 11.2.4.5. Strategies,; 11.2.4.6. financials (Based on Availability); 11.2.5. F. Hoffmann-La Roche Ltd; 11.2.5.1. Overview,; 11.2.5.2. Products,; 11.2.5.3. SWOT Analysis,; 11.2.5.4. Recent Developments,; 11.2.5.5. Strategies,; 11.2.5.6. financials (Based on Availability); 11.2.6. Aurobindo Pharma Limited; 11.2.6.1. Overview,; 11.2.6.2. Products,; 11.2.6.3. SWOT Analysis,; 11.2.6.4. Recent Developments,; 11.2.6.5. Strategies,; 11.2.6.6. financials (Based on Availability); 11.2.7. Otsuka Pharmaceutical Co., Ltd.; 11.2.7.1. Overview,; 11.2.7.2. Products,; 11.2.7.3. SWOT Analysis,; 11.2.7.4. Recent Developments,; 11.2.7.5. Strategies,; 11.2.7.6. financials (Based on Availability); 11.2.8. Janssen Pharmaceuticals, Inc.; 11.2.8.1. Overview,; 11.2.8.2. Products,; 11.2.8.3. SWOT Analysis,; 11.2.8.4. Recent Developments,; 11.2.8.5. Strategies,; 11.2.8.6. financials (Based on Availability); 11.2.9. Teva Pharmaceutical Industries Ltd.; 11.2.9.1. Overview,; 11.2.9.2. Products,; 11.2.9.3. SWOT Analysis,; 11.2.9.4. Recent Developments,; 11.2.9.5. Strategies,; 11.2.9.6. financials (Based on Availability); 11.2.10. H. Lundbeck A/S; 11.2.10.1. Overview,; 11.2.10.2. Products,; 11.2.10.3. SWOT Analysis,; 11.2.10.4. Recent Developments,; 11.2.10.5. Strategies,; 11.2.10.6. financials (Based on Availability); 11.2.11. Other Prominent Players; 11.2.11.1. Overview,; 11.2.11.2. Products,; 11.2.11.3. SWOT Analysis,; 11.2.11.4. Recent Developments,; 11.2.11.5. Strategies,; 11.2.11.6. financials (Based on Availability)